Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-264 in adults with type 1 diabetes
NL-OMON59263Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of VX-264 in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability and Change from baseline in peak C-peptide during MMTT at Day 90. Started Jul 2023; status: active, not recruiting.
02
Drugs
VX-264
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59263.